Altimmune, Inc..
American biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 35
What's happening
Earlier this month
One to three months ago
-
X4 Pharmaceuticals and Altimmune, Inc. are small-cap healthcare companies trading on the Nasdaq stock exchange.Some support1 report
-
Citigroup provided a stock rating for Altimmune, Inc.Some support1 report
-
Altimmune tests Pemvidutide for MASH treatment and plans FDA engagement, attracting attention from Goldman Sachs.Some support2 reports2 developments inside
-
Altimmune's Pemvidutide received Breakthrough Therapy Designation from the FDA.Some support2 reports
Gone quiet
No new reports in 90+ days-
Altimmune, Inc. is seeking an End-of-Phase 2 meeting with the FDA regarding the results of pemvidutide trials for MASH.Some support2 reports
-
MarketBeat aggregated analyst ratings for Altimmune, Inc., while Leerink Partners began coverage of the stock.Some support1 report
-
Mannatech and Altimmune, Inc. are listed on Nasdaq and operate across the Americas, Europe, Africa, and the Middle East.Some support1 report
-
Altimmune initiated the RESTORE Phase 2 trial.Speculative1 report
-
Altimmune, Inc. appointed Jerry Durso as Chairman of the board while developing therapeutics for MASH.Some support3 reports
-
BlackRock holds a 7.6% stake in Altimmune, Inc. as of August 13, 2025.Some support1 report
-
Altimmune, Inc.'s drug received Fast Track designation from the FDA on August 19, 2025. The WHO risk drinking level is a trial endpoint.Some support2 reports
-
Altimmune, Inc. participated in a conference in Boston on August 26, 2025.Some support1 report
-
Altimmune, Inc. held investor conferences in Miami Beach, FL, and New York, NY, on May 27, 2026.Some support1 report
-
Altimmune, Inc. presented data on pemvidutide for MASH at EASL Congress 2026, held in Barcelona, led by principal investigator Mazen Noureddin.Well supported4 reports
No events began in the chosen period. Widen it, or reset.
Around Altimmune, Inc. this week
News at the entities that move Altimmune, Inc. most-
FDA StructuralFDA accepted Axion BioSystems' Letter of Intent (LOI) for a neural assay on November 10, 2026.Moves Altimmune, Inc.
-
Nasdaq StructuralStrong quarterly results and foreign fund inflows supported technology stocks and lifted investor sentiment across markets.Moves Altimmune, Inc.
-
Citigroup Mentioned togetherAmundi increased its stake in Kroger stock and Citigroup issued a price objective on Kroger shares.Moves Altimmune, Inc.
-
Leerink partners Mentioned togetherLeerink Partners began coverage on Shattuck Labs shares, and TD Cowen subsequently raised the shares to a strong-buy rating.Moves Altimmune, Inc.
-
mash OperationalDenver hosts the annual MASH meeting, featuring presentations from Novo Nordisk and Gilead Sciences on new therapies.Moves Altimmune, Inc.
-
MarketBeat Mentioned togetherMarketBeat provided average stock rating data for SS Innovations International, Inc. on June 6, 2026.Moves Altimmune, Inc.
Connections
The 16 strongest of 35, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nasdaq Structural
Altimmune, Inc. is formally listed and trades on the Nasdaq stock exchange.
-
FDA Structural
The FDA formally regulates Altimmune's drug development, granting designations like Fast Track and Breakthrough Therapy.
-
Scott Harris Structural
Scott Harris serves as the Chief Medical Officer of Altimmune, Inc.
-
mash Operational
Altimmune is actively developing and testing pemvidutide as a therapeutic approach for MASH disease.
-
Altimmune leverages the EASL platform by presenting its scientific data at their annual congress.
-
MarketBeat Mentioned together
MarketBeat functions as a data aggregator, collecting and presenting analyst ratings concerning Altimmune's business performance.
-
Grifols Mentioned together
Both companies are mentioned in the same context as healthcare companies being compared.
-
Citigroup Mentioned together
Citigroup provided a stock rating and analysis for Altimmune, Inc.
Show all 16 connections
-
Miami Beach Shared context
Altimmune utilizes Miami Beach as the location for its investor conferences.
-
New York Shared context
Altimmune holds investor conferences in New York City, establishing a locational context for its operations.
-
Amsterdam Shared context
Altimmune presented analyses at a congress held in Amsterdam.
-
Mash Mentioned together
Both entities are mentioned in the context of developing therapeutics for MASH.
-
Gaithersburg Shared context
Altimmune, Inc. is located and operates within the geographical context of Gaithersburg.
-
Leerink partners Mentioned together
Leerink Partners began providing financial coverage and analysis of Altimmune's stock.
-
Barcelona Shared context
Altimmune presented findings at a conference held in Barcelona.
-
JPEG Mentioned together
No evidence linking JPEG to Altimmune, Inc. was found in the provided timeline.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
2 eventsShow 2 earlier months
July 2026
1 eventJune 2026
10 events- Altimmune tests Pemvidutide for MASH treatment and plans FDA engagement, attracting attention from Goldman Sachs.
- MarketBeat aggregated analyst ratings for Altimmune, Inc., while Leerink Partners began coverage of the stock.
- Mannatech and Altimmune, Inc. are listed on Nasdaq and operate across the Americas, Europe, Africa, and the Middle East.
- Altimmune initiated the RESTORE Phase 2 trial.
- Altimmune, Inc. appointed Jerry Durso as Chairman of the board while developing therapeutics for MASH.
- BlackRock holds a 7.6% stake in Altimmune, Inc. as of August 13, 2025.
- Altimmune, Inc.'s drug received Fast Track designation from the FDA on August 19, 2025. The WHO risk drinking level is a trial endpoint.
- Altimmune, Inc. participated in a conference in Boston on August 26, 2025.
- Altimmune, Inc. held investor conferences in Miami Beach, FL, and New York, NY, on May 27, 2026.
- Altimmune, Inc. presented data on pemvidutide for MASH at EASL Congress 2026, held in Barcelona, led by principal investigator Mazen Noureddin.